PE20190169A1 - Nueva sal de adicion de acido de 1-(5-(2,4-difluorfenil)-1-(3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina - Google Patents
Nueva sal de adicion de acido de 1-(5-(2,4-difluorfenil)-1-(3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanaminaInfo
- Publication number
- PE20190169A1 PE20190169A1 PE2018001575A PE2018001575A PE20190169A1 PE 20190169 A1 PE20190169 A1 PE 20190169A1 PE 2018001575 A PE2018001575 A PE 2018001575A PE 2018001575 A PE2018001575 A PE 2018001575A PE 20190169 A1 PE20190169 A1 PE 20190169A1
- Authority
- PE
- Peru
- Prior art keywords
- methylmethanamine
- sulfonyl
- acid addition
- addition salt
- new
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- -1 2,4-DIFLUORPHENYL Chemical class 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- OUNXGNDVWVPCOL-UHFFFAOYSA-N 1-[5-(2,4-difluorophenyl)-1-(3-fluorophenyl)sulfonyl-4-methoxypyrrol-3-yl]-N-methylmethanamine Chemical compound FC1=C(C=CC(=C1)F)C1=C(C(=CN1S(=O)(=O)C1=CC(=CC=C1)F)CNC)OC OUNXGNDVWVPCOL-UHFFFAOYSA-N 0.000 abstract 1
- 208000007882 Gastritis Diseases 0.000 abstract 1
- 206010061172 Gastrointestinal injury Diseases 0.000 abstract 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 abstract 1
- 108010083204 Proton Pumps Proteins 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000008029 eradication Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000000689 peptic esophagitis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Se refiere a un metodo de preparacion de una nueva sal de adicion de acido de 1-(5-(2,4-difluorfenil)-1-((3-fluorfenil)sulfonil)-4-metoxi-1H-pirrol-3-il)-N-metilmetanamina. Tambien se refiere a una composicion farmaceutica. Dicho compuesto tiene, no solo actividad inhibitoria de la bomba protonica, actividad inhibitoria del dano gastrico y efecto mejorador de factores defensivos, sino, ademas, excelente actividad de erradicacion contra H. pylori, y, por lo tanto, puede usarse eficazmente para la prevencion y el tratamiento de lesion gastrointestinal debida a ulcera del tracto gastrointestinal, gastritis, esofagitis por reflujo, o H. pylori.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160036081 | 2016-03-25 | ||
| KR1020170018336A KR20170113040A (ko) | 2016-03-25 | 2017-02-09 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염 |
| PCT/KR2017/002913 WO2017164575A1 (en) | 2016-03-25 | 2017-03-17 | Novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190169A1 true PE20190169A1 (es) | 2019-02-01 |
Family
ID=60141235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001575A PE20190169A1 (es) | 2016-03-25 | 2017-03-17 | Nueva sal de adicion de acido de 1-(5-(2,4-difluorfenil)-1-(3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10487053B2 (es) |
| EP (1) | EP3433232B1 (es) |
| JP (1) | JP6609065B2 (es) |
| KR (2) | KR20170113040A (es) |
| CN (1) | CN108602771B (es) |
| AR (1) | AR107964A1 (es) |
| AU (1) | AU2017238917B2 (es) |
| CA (1) | CA3014753C (es) |
| CL (1) | CL2018002415A1 (es) |
| CO (1) | CO2018008834A2 (es) |
| DO (2) | DOP2018000191A (es) |
| ES (1) | ES2811478T3 (es) |
| HR (1) | HRP20201571T1 (es) |
| HU (1) | HUE053741T2 (es) |
| JO (1) | JOP20170071B1 (es) |
| MA (1) | MA43832B1 (es) |
| MX (1) | MX379775B (es) |
| MY (1) | MY196355A (es) |
| NZ (1) | NZ745267A (es) |
| PE (1) | PE20190169A1 (es) |
| PH (1) | PH12018501845B1 (es) |
| PL (1) | PL3433232T3 (es) |
| PT (1) | PT3433232T (es) |
| RS (1) | RS60857B1 (es) |
| SG (1) | SG11201806968RA (es) |
| SI (1) | SI3433232T1 (es) |
| TN (1) | TN2018000269A1 (es) |
| TW (1) | TWI607753B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102081920B1 (ko) * | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| KR102233455B1 (ko) * | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102126576B1 (ko) | 2018-09-19 | 2020-06-24 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
| EP4079293A4 (en) * | 2019-12-18 | 2024-01-03 | Daewoong Pharmaceutical Co., Ltd. | Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrole-3-yl)-n-methylmethaneamine |
| HUE070031T2 (hu) * | 2020-06-17 | 2025-05-28 | Ildong Pharmaceutical Co Ltd | Új savszekréciós inhibitor és alkalmazása |
| EP4245298A4 (en) * | 2020-12-18 | 2024-10-30 | Daewoong Pharmaceutical Co., Ltd. | NEW FORMULATION FOR ORAL ADMINISTRATION, COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE |
| JP2024519586A (ja) * | 2021-05-26 | 2024-05-17 | デウン ファーマシューティカル カンパニー リミテッド | １－（５－（２，４－ジフルオロフェニル）－１－（（３－フルオロフェニル）スルホニル）－４－メトキシ－１ｈ－ピロール－３－イル）－ｎ－メチルメタンアミンを含む新規な注射用製剤 |
| TW202304426A (zh) * | 2021-05-26 | 2023-02-01 | 南韓商大熊製藥股份有限公司 | 用於注射之包含１－（５－（２，４－二氟苯基）－１－（（３－氟苯基）磺醯基）－４－甲氧基－１ｈ－吡咯－３－基）－ｎ－甲基甲胺的新調配物 |
| MX2023013985A (es) * | 2021-05-26 | 2023-12-12 | Daewoong Pharmaceutical Co Ltd | Contenedor de medicina que comprende la composicion farmaceutica liquida de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4- metoxi-1h-pirrol-3-il)-n-metilmetanamina. |
| KR20240119083A (ko) * | 2021-12-15 | 2024-08-06 | 일동제약(주) | 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| WO2023113487A1 (ko) * | 2021-12-15 | 2023-06-22 | 주식회사 대웅제약 | 펙수프라잔 주사제 조성물 용법용량 |
| US20250084026A1 (en) * | 2021-12-15 | 2025-03-13 | Ildong Pharmaceutical Co., Ltd. | Novel salt of 1-sulfonyl pyrrole derivative, preparation method thereof and pharmaceutical composition comprising thereof |
| US20250268862A1 (en) * | 2022-04-25 | 2025-08-28 | Daewoong Pharmaceutical Co., Ltd. | Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions |
| KR20240170934A (ko) * | 2022-05-23 | 2024-12-05 | 일동제약(주) | 6-메톡시피리딘-3-일 유도체의 제조방법 |
| TW202411215A (zh) * | 2022-05-23 | 2024-03-16 | 南韓商日東製藥股份有限公司 | ６－甲氧基吡啶－３－基衍生物之製造方法 |
| CN117820193A (zh) * | 2022-09-29 | 2024-04-05 | 安徽皓元药业有限公司 | 一种非苏拉赞盐酸盐晶型a及其制备方法 |
| KR20240127136A (ko) * | 2023-02-15 | 2024-08-22 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048909B2 (en) | 2004-09-30 | 2011-11-01 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
| US7977488B2 (en) * | 2005-08-30 | 2011-07-12 | Takeda Pharmaceutical Company Limited | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
| US7994205B2 (en) * | 2006-03-31 | 2011-08-09 | Takeda Pharmaceutical Company Limited | Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors |
| US20100113524A1 (en) * | 2006-09-19 | 2010-05-06 | Garst Michael E | Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety |
| US8933105B2 (en) * | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| WO2014075575A1 (zh) * | 2012-11-19 | 2014-05-22 | 江苏豪森药业股份有限公司 | 吡咯磺酰类衍生物、其制备方法及其在医药上的应用 |
| US9487485B2 (en) * | 2013-02-28 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Method for producing sulfonyl chloride compound |
| KR102084185B1 (ko) * | 2013-08-29 | 2020-03-04 | 주식회사 대웅제약 | 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법 |
| CN104447490B (zh) * | 2014-11-19 | 2017-06-06 | 连云港恒运医药有限公司 | 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途 |
| CN104447491B (zh) * | 2014-11-19 | 2017-06-23 | 连云港恒运医药有限公司 | 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途 |
| KR101613245B1 (ko) * | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
-
2017
- 2017-02-09 KR KR1020170018336A patent/KR20170113040A/ko not_active Ceased
- 2017-03-17 RS RS20201178A patent/RS60857B1/sr unknown
- 2017-03-17 JP JP2018549922A patent/JP6609065B2/ja active Active
- 2017-03-17 ES ES17770545T patent/ES2811478T3/es active Active
- 2017-03-17 MY MYPI2018703343A patent/MY196355A/en unknown
- 2017-03-17 HU HUE17770545A patent/HUE053741T2/hu unknown
- 2017-03-17 US US16/073,388 patent/US10487053B2/en active Active
- 2017-03-17 HR HRP20201571TT patent/HRP20201571T1/hr unknown
- 2017-03-17 MA MA43832A patent/MA43832B1/fr unknown
- 2017-03-17 AU AU2017238917A patent/AU2017238917B2/en active Active
- 2017-03-17 PT PT177705456T patent/PT3433232T/pt unknown
- 2017-03-17 CN CN201780008658.9A patent/CN108602771B/zh active Active
- 2017-03-17 MX MX2018009220A patent/MX379775B/es unknown
- 2017-03-17 TN TNP/2018/000269A patent/TN2018000269A1/en unknown
- 2017-03-17 SI SI201730396T patent/SI3433232T1/sl unknown
- 2017-03-17 SG SG11201806968RA patent/SG11201806968RA/en unknown
- 2017-03-17 NZ NZ745267A patent/NZ745267A/en unknown
- 2017-03-17 PL PL17770545T patent/PL3433232T3/pl unknown
- 2017-03-17 PE PE2018001575A patent/PE20190169A1/es unknown
- 2017-03-17 CA CA3014753A patent/CA3014753C/en active Active
- 2017-03-17 EP EP17770545.6A patent/EP3433232B1/en active Active
- 2017-03-21 TW TW106109336A patent/TWI607753B/zh active
- 2017-03-22 JO JOP/2017/0071A patent/JOP20170071B1/ar active
- 2017-03-23 AR ARP170100727A patent/AR107964A1/es active IP Right Grant
-
2018
- 2018-08-23 CL CL2018002415A patent/CL2018002415A1/es unknown
- 2018-08-24 CO CONC2018/0008834A patent/CO2018008834A2/es unknown
- 2018-08-30 PH PH12018501845A patent/PH12018501845B1/en unknown
- 2018-08-31 DO DO2018000191A patent/DOP2018000191A/es unknown
-
2020
- 2020-08-24 KR KR1020200106002A patent/KR102417830B1/ko active Active
-
2021
- 2021-01-06 DO DO2021000001A patent/DOP2021000001A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190169A1 (es) | Nueva sal de adicion de acido de 1-(5-(2,4-difluorfenil)-1-(3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina | |
| DOP2021000213A (es) | Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composición farmacéutica que comprende los mismos | |
| PE20190170A1 (es) | Nueva forma cristalina de sal de 1-(5-(2,4-difluorfenil)-1-(3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| PH12016501357B1 (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
| MX2021009909A (es) | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. | |
| SG11201805791RA (en) | COMPOSITION FOR INCREASING EXPRESSION OF PGC-1α | |
| EA201790453A3 (ru) | Новая соль присоединения кислоты 1-(5-(2,4-дифторфенил)-1-((3- фторфенил)сульфонил)-4-метокси-1h-пиррол-3-ил)-n-метилметанамина | |
| EA201991688A1 (ru) | Фармацевтические комбинации для лечения рака | |
| MX2025004900A (es) | Tratamiento de verrugas | |
| BR112016028561A2 (pt) | composição, forma de dosagem, e, métodos para reduzir o risco para mortalidade em um indivíduo, o risco para uma doença ou condição em um indivíduo, triglicerídeos em um sangue de indivíduo, a frequência cardíaca em repouso de um indivíduo, o colesterol de lipoproteína de densidade não alta em um indivíduo, o colesterol total em um indivíduo, a apolipoproteína b em um sangue de indivíduo, pressão sanguínea sistólica em um indivíduo e a pressão sanguínea diastólica em um indivíduo, para prolongar a vida de um indivíduo, para tratar hipertrigliceridemia em um indivíduo e para aumentar um índice de ômega-3 em células vermelhas do sangue de um indivíduo. | |
| WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
| EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| AR099416A1 (es) | Terapia combinada para la hipertensión resistente | |
| PH12020500393A1 (en) | Mpges-1 inhibitor for the treatment of osteoarthritis pain | |
| CL2019001529A1 (es) | Compuestos de quinona y acido ascórbico para el tratamiento de la enfermedad de chagas. | |
| WO2018203751A8 (en) | Therapeutic effects of guanabenz treatment in vanishing white matter | |
| MD4712B1 (ro) | Utilizarea tetrasalicilatului de bariu-cupru în calitate de inhibitor al proliferării fungilor Сryptococcus neoformans | |
| MX2018016372A (es) | Composicion para controlar enfermedades de reflujo gastroesofagico. | |
| PE20170200A1 (es) | Composicion farmaceutica que combina un anticonvulsivante y un derivado del acido nicotinico | |
| UA93426U (uk) | Композиція у вигляді гелю для лікування вугрової хвороби |